首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells.
【24h】

Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells.

机译:microRNA-17-92簇的成员在内皮细胞中表现出细胞内在的抗血管生成功能。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

MicroRNAs are endogenously expressed small noncoding RNAs that regulate gene expression on the posttranscriptional level. The miR-17-92 cluster (encoding miR-17, -18a, -19a/b, -20a, and miR-92a) is highly expressed in tumor cells and is up-regulated by ischemia. Whereas miR-92a was recently identified as negative regulator of angiogenesis, the specific functions of the other members of the cluster are less clear. Here we demonstrate that overexpression of miR-17, -18a, -19a, and -20a significantly inhibited 3-dimensional spheroid sprouting in vitro, whereas inhibition of miR-17, -18a, and -20a augmented endothelial cell sprout formation. Inhibition of miR-17 and miR-20a in vivo using antagomirs significantly increased the number of perfused vessels in Matrigel plugs, whereas antagomirs that specifically target miR-18a and miR-19a were less effective. However, systemic inhibition of miR-17/20 did not affect tumor angiogenesis. Further mechanistic studies showed that miR-17/20 targets several proangiogenic genes. Specifically, Janus kinase 1 was shown to be a direct target of miR-17. In summary, we show that miR-17/20 exhibit a cell-intrinsic antiangiogenic activity in endothelial cells. Inhibition of miR-17/20 specifically augmented neovascularization of Matrigel plugs but did not affect tumor angiogenesis indicating a context-dependent regulation of angiogenesis by miR-17/20 in vivo.
机译:MicroRNA是内源表达的小的非编码RNA,可在转录后水平上调控基因表达。 miR-17-92簇(编码miR-17,-18a,-19a / b,-20a和miR-92a)在肿瘤细胞中高度表达,并被缺血上调。尽管miR-92a最近被鉴定为血管生成的负调节剂,但该簇其他成员的具体功能尚不清楚。在这里,我们证明了miR-17,-18a,-19a和-20a的过度表达在体外显着抑制了3D球形球体发芽,而对miR-17,-18a和-20a的抑制则增加了内皮细胞发芽的形成。使用Antagomirs在体内抑制miR-17和miR-20a显着增加了Matrigel栓塞中灌注血管的数量,而专门针对miR-18a和miR-19a的Antagomirs效果较差。但是,对miR-17 / 20的全身抑制作用不会影响肿瘤血管生成。进一步的机理研究表明,miR-17 / 20靶向几种促血管生成基因。具体而言,显示Janus激酶1是miR-17的直接靶标。总之,我们表明miR-17 / 20在内皮细胞中表现出细胞内在的抗血管生成活性。对miR-17 / 20的抑制特异性地增强了Matrigel栓的新血管形成,但不影响肿瘤血管生成,表明miR-17 / 20在体内对血管生成的背景依赖性调节。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号